Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Daniel Gold
AddedMar 31, 2024
UpdatedMay 31, 2026
Daniel Gold

Daniel Gold

Founder, Mmrglobal

LinkedIn

Daniel Gold's Career

Mmrglobal
Mmrglobal

Los Angeles, CA, US

Founder
Lite Strategy
Lite Strategy

San Diego, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Daniel Gold's Career

Mmrglobal
Mmrglobal
Investment FirmInvestment Firm$33.9k52000Los Angeles, CA, US
Founder

Leadership at Mmrglobal

Mike FinleyMike FinleyBoard Member
Jason R PfeifferJason R PfeifferBoard Member
Scott KlineScott KlineBoard Member
Titus DayTitus DayBoard Member
Lite Strategy
Lite Strategy
Public$160.4M462000San Diego, CA, US
Board Member· Board

Recent news

Zepto raises another $350M amid retail upheaval in IndiaTechCrunch · 2024

Leadership at Lite Strategy

David UrsoDavid UrsoCEO
Charles BalticCharles BalticBoard Member
Norman SelbyNorman SelbyBoard Member
Tom ReynoldsTom ReynoldsBoard Member
Christine A. WhiteChristine A. WhiteBoard Member

Similar to Lite Strategy

Revolution MedicinesRevolution MedicinesRedwood City, CA, USOncology Therapiesest. 2014Revolution MedicinesRedwood City, CA, US · est. 2014

US-based Revolution Medicines, Inc. discovers novel oncology therapies targeting elusive growth pathways globally.

Public · $1.1B246
ImageneBioImageneBioBoston, MA, USCancer Therapiesest. 2016ImageneBioBoston, MA, US · est. 2016

Ikena: A targeted oncology firm developing novel therapies to combat cancer's formation and spread.

Public · $209M68
Innovo TherapeuticsInnovo TherapeuticsSan Diego, CA, USAnti-Cancer Drugsest. 2021Innovo TherapeuticsSan Diego, CA, US · est. 2021

San Diego-based Innovo Therapeutics develops anti-cancer drugs targeting protein breakdown.

Seed · $200M11
Karyopharm TherapeuticsKaryopharm TherapeuticsNewton, MA, USPharmaceuticalsest. 2008Karyopharm TherapeuticsNewton, MA, US · est. 2008

US-based Karyopharm Therapeutics offers oncology-focused pharmaceutical solutions, specializing in multiple myeloma treatments.

Public · $546.7M385

Daniel Gold's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuHaeil YiHaeil YiCo-Founder · DunamuHyoung-nyon KimHyoung-nyon KimCo-Founder · Dunamu

People Similar to Daniel Gold

Justin IchidaJustin IchidaCo-Founder · AcuraStemMark GoldsteinMark GoldsteinFounder · Advisors.fundGilad GlickGilad GlickBoard Member · Beta BionicsMichael BauerMichael BauerBoard Member · NumabBryon WolfBryon WolfCo-Founder · OnMedJane GrossJane GrossBoard Member · aTyr Pharma